T

TMS Co Ltd
TSE:4891

Watchlist Manager
TMS Co Ltd
TSE:4891
Watchlist
Price: 212 JPY -3.2% Market Closed
Market Cap: 8.5B JPY
Have any thoughts about
TMS Co Ltd?
Write Note

TMS Co Ltd
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

TMS Co Ltd
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
T
TMS Co Ltd
TSE:4891
Capital Expenditures
-ÂĄ3.4m
CAGR 3-Years
-89%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
GNI Group Ltd
TSE:2160
Capital Expenditures
-ÂĄ1.5B
CAGR 3-Years
-35%
CAGR 5-Years
-20%
CAGR 10-Years
-22%
PeptiDream Inc
TSE:4587
Capital Expenditures
-ÂĄ2B
CAGR 3-Years
-18%
CAGR 5-Years
-60%
CAGR 10-Years
-36%
Takara Bio Inc
TSE:4974
Capital Expenditures
-ÂĄ2.6B
CAGR 3-Years
33%
CAGR 5-Years
19%
CAGR 10-Years
7%
Pharma Foods International Co Ltd
TSE:2929
Capital Expenditures
-ÂĄ973m
CAGR 3-Years
-78%
CAGR 5-Years
-28%
CAGR 10-Years
-55%
C
Cuorips Inc
TSE:4894
Capital Expenditures
-ÂĄ35.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

TMS Co Ltd
Glance View

Market Cap
8.5B JPY
Industry
Biotechnology

TMS Co., Ltd. engages in the research and development of pharmaceutical products and medical devices. The company is headquartered in Fuchu-Shi, Tokyo-To and currently employs 8 full-time employees. The company went IPO on 2022-11-22. The firm conducts research and development of drug candidate substances based on the research and development results of academia and other research institutions. The current pipeline consists of drug candidates targeting soluble epoxide hydrolase (sEH), one of the enzymes in the human body. sEH inhibition has been shown to provide anti-inflammatory effects and the Company is developing sEH inhibitors for a variety of inflammatory diseases. The lead pipeline, TMS-007, has an anti-inflammatory effect by inhibiting sEH and a thrombolytic effect by acting on plasminogen, and will be clinically developed for acute cerebral infarction. TMS-008, a follow-on product in the pipeline, is being developed for various inflammatory diseases and is currently undergoing pre-clinical studies.

Intrinsic Value
103.44 JPY
Overvaluation 51%
Intrinsic Value
Price
T

See Also

What is TMS Co Ltd's Capital Expenditures?
Capital Expenditures
-3.4m JPY

Based on the financial report for Feb 29, 2024, TMS Co Ltd's Capital Expenditures amounts to -3.4m JPY.

What is TMS Co Ltd's Capital Expenditures growth rate?
Capital Expenditures CAGR 3Y
-89%

Over the last year, the Capital Expenditures growth was 76%. The average annual Capital Expenditures growth rates for TMS Co Ltd have been -89% over the past three years .

Back to Top